Related Experiment Video
Updated: Apr 27, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
12.7K
Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation
M Takahashi1, T Saito1, M Ito1
1Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
The Pharmacogenomics Journal
|July 9, 2014
Summary
Genetic variations in cytochrome P450 2C19 (CYP2C19) significantly impact clopidogrel metabolism. Many CYP2C19 variants show little to no activity, explaining drug efficacy differences.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Enzymology
Background:
- Genetic variations in cytochrome P450 2C19 (CYP2C19) are a major source of interindividual differences in drug response.
- CYP2C19 plays a crucial role in metabolizing clopidogrel, an important antiplatelet medication.
- Polymorphisms in CYP2C19 lead to significant variations in clopidogrel's therapeutic efficacy.
Purpose of the Study:
- To investigate the in vitro oxidation activity of 21 CYP2C19 variants with amino acid substitutions on clopidogrel.
- To characterize the kinetic parameters of clopidogrel 2-oxidation mediated by these CYP2C19 variants.
Main Methods:
- Heterologous expression of 21 CYP2C19 variants in COS-7 cells.
- In vitro assessment of clopidogrel 2-oxidation kinetics for each variant.
- Comparison of variant activity against the wild-type CYP2C19.1B protein.
Main Results:
- Twelve out of 21 evaluated CYP2C19 variants demonstrated no or markedly reduced activity in clopidogrel oxidation.
- Specific variants like CYP2C19.5A, CYP2C19.5B, CYP2C19.6, CYP2C19.8, CYP2C19.9, CYP2C19.10, CYP2C19.14, CYP2C19.16, CYP2C19.19, CYP2C19.22, CYP2C19.24, and CYP2C19.25 showed significantly impaired function.
- The study provides a detailed profile of clopidogrel metabolic activity across numerous CYP2C19 variants.
Conclusions:
- This comprehensive in vitro analysis elucidates the functional impact of various CYP2C19 genetic variants on clopidogrel metabolism.
- Understanding these specific metabolic activities is vital for interpreting in vivo pharmacogenetic studies and predicting clopidogrel response.
- The findings contribute to personalized medicine approaches by highlighting genetic factors influencing antiplatelet therapy effectiveness.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
330
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
330
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
156
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
01:27Pharmacogenetics of Drug Metabolism: Overview
191
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189
01:27Principles of Pharmacogenetics: Types of Genetic Variants
135
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
135
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
93
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93